KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Inventory: 2020-2024

Historic Inventory for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Dec 2024 value amounting to $39.2 million.

  • Aurinia Pharmaceuticals' Inventory rose 15.70% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 15.70%. This contributed to the annual value of $39.2 million for FY2024, which is 1.20% down from last year.
  • Aurinia Pharmaceuticals' Inventory amounted to $39.2 million in FY2024, which was down 1.20% from $39.7 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Inventory registered a high of $39.7 million during FY2023, and its lowest value of $13.9 million during FY2020.
  • For the 3-year period, Aurinia Pharmaceuticals' Inventory averaged around $34.6 million, with its median value being $39.2 million (2024).
  • In the last 5 years, Aurinia Pharmaceuticals' Inventory skyrocketed by 60.41% in 2023 and then decreased by 1.20% in 2024.
  • Yearly analysis of 5 years shows Aurinia Pharmaceuticals' Inventory stood at $13.9 million in 2020, then surged by 38.77% to $19.3 million in 2021, then climbed by 28.08% to $24.8 million in 2022, then surged by 60.41% to $39.7 million in 2023, then fell by 1.20% to $39.2 million in 2024.